Dogwood Therapeutics completes enrolment in Halneuron CINP Phase 2b
Dogwood Therapeutics has completed patient enrolment in its Phase 2b trial of Halneuron in chemotherapy-induced neuropathic pain (CINP), the Nasdaq-listed company announced on 14 September 2026. The study enrolled 239 participants, reaching the upper end of the planned target range, with topline results expected in November 2026.
CINP is a condition with no currently approved FDA treatments, which Dogwood says gives Halneuron a potential regulatory opening should the study read out positively. The candidate has already received FDA Fast Track designation for the indication, a status that allows more frequent agency interactions and can accelerate the review process.
The trial in detail
The HAL-CINP study (NCT06848348) is a randomised, placebo-controlled trial evaluating Halneuron in patients with moderate to severe neuropathic pain caused by prior platinum or taxane-based chemotherapy. Participants receive eight subcutaneous doses over a 14-day period and are followed for a total of 28 days. The primary endpoint is the change from baseline to week four in the weekly average of daily pain intensity scores. Secondary measures will examine effects on sleep, fatigue, neuropathy symptoms and broader patient health. The trial is running across approximately 25 sites in the United States.
Halneuron is a selective Nav1.7 voltage-gated sodium channel modulator, a mechanistic class that has attracted sustained interest in pain research given the channel's role in pain signal transmission. Unlike opioid-based analgesics, Nav1.7 modulators are not associated with the dependency and tolerance concerns that have made opioid prescribing increasingly restricted in the United States. Greg Duncan, chief executive of Dogwood, said high interest from healthcare providers and patients drove enrolment to the top of the projected range, adding that an encouraging interim analysis had reinforced the company's confidence in the programme.
Market context and competitive landscape
The non-opioid pain market is an active area for both established pharmaceutical groups and smaller clinical-stage companies. Several candidates targeting Nav1.7 or related sodium channels have progressed through development over the past decade, though the pathway has proved challenging; a number of high-profile programmes, including efforts from larger players, have not translated preclinical promise into Phase 3 success. Dogwood's positioning in a specific oncology-adjacent pain indication, where there is a clear unmet need and no approved standard of care, may offer a more defined regulatory route than broader neuropathic pain claims.
Beyond Halneuron, Dogwood's pipeline includes SP16 IV, an LRP1 agonist with preclinical data suggesting anti-inflammatory and nerve-repair properties. A Phase 1b trial in chemotherapy-induced peripheral neuropathy is fully funded by the National Cancer Institute, reducing near-term capital requirements for that programme.
The November 2026 topline readout will be closely watched. If the primary endpoint is met, Dogwood is likely to seek an end-of-Phase-2 meeting with the FDA to discuss a pivotal study design. A negative or inconclusive result would raise significant questions about the company's runway and pipeline prioritisation, given that Halneuron is the lead asset for a development-stage business.